Repligen (NASDAQ:RGEN) Shares Gap Down to $160.98

Shares of Repligen Co. (NASDAQ:RGEN) gapped down prior to trading on Thursday . The stock had previously closed at $160.98, but opened at $154.59. Repligen shares last traded at $156.00, with a volume of 183,643 shares trading hands.

Analyst Ratings Changes

RGEN has been the subject of a number of analyst reports. KeyCorp boosted their price target on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Stifel Nicolaus boosted their price target on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. Finally, JPMorgan Chase & Co. boosted their price target on Repligen from $170.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, December 20th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $196.70.

Repligen Price Performance

The company has a 50 day moving average price of $190.02 and a 200-day moving average price of $173.20. The company has a quick ratio of 5.75, a current ratio of 7.02 and a debt-to-equity ratio of 0.26. The company has a market cap of $8.82 billion, a price-to-earnings ratio of 219.36, a P/E/G ratio of 5.38 and a beta of 1.02.

Repligen (NASDAQ:RGEN) last announced its earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The business had revenue of $155.74 million for the quarter, compared to analysts’ expectations of $155.38 million. During the same period in the prior year, the business posted $0.68 earnings per share. The firm’s revenue was down 16.6% on a year-over-year basis. As a group, equities research analysts predict that Repligen Co. will post 1.46 EPS for the current fiscal year.

Insiders Place Their Bets

In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the transaction, the vice president now directly owns 24,260 shares in the company, valued at approximately $4,699,889.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, VP Ralf Kuriyel sold 3,517 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the transaction, the vice president now directly owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Karen A. Dawes sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total value of $193,350.00. Following the transaction, the director now directly owns 87,367 shares in the company, valued at $16,892,409.45. The disclosure for this sale can be found here. In the last three months, insiders have sold 25,597 shares of company stock worth $5,039,532. Corporate insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Institutional investors and hedge funds have recently bought and sold shares of the stock. Fortis Capital Advisors LLC purchased a new stake in Repligen in the 4th quarter valued at $35,000. Benjamin F. Edwards & Company Inc. raised its position in Repligen by 152.1% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 146 shares during the last quarter. Park Place Capital Corp raised its position in Repligen by 90.2% in the 3rd quarter. Park Place Capital Corp now owns 253 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 120 shares during the last quarter. Principal Securities Inc. purchased a new stake in Repligen in the 4th quarter valued at $48,000. Finally, Signaturefd LLC raised its position in Repligen by 44.1% in the 3rd quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 86 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.